Contribution of Acute-Phase Proteins and Cardiovascular Risk Factors to Erythrocyte Aggregation in Normolipidemic and Hyperlipidemic Individuals

Xiaoduan Weng; Ghislaine O. Roederer; Raymond Beaulieu; Guy Cloutier

doi:10.1055/s-0037-1615386

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 80(06): 903-908
DOI: 10.1055/s-0037-1615386

Letters to the Editor

Schattauer GmbH

Contribution of Acute-Phase Proteins and Cardiovascular Risk Factors to Erythrocyte Aggregation in Normolipidemic and Hyperlipidemic Individuals

Xiaoduan Weng

¹Laboratory of Biomedical Engineering, Clinical Research Institute of Montréal, Québec, Canada

,

Ghislaine O. Roederer

²Laboratory of Hyperlipidemia and Atherosclerosis, Clinical Research Institute of Montréal, Québec, Canada

,

Raymond Beaulieu

³Division of Oncology and Hematology, University of Montréal Hospital, Pavilion Hôtel-Dieu, Québec, Canada

,

Guy Cloutier

¹Laboratory of Biomedical Engineering, Clinical Research Institute of Montréal, Québec, Canada

› Author Affiliations

Abstract

Summary

Background. Numerous studies have demonstrated that elevated concentrations of acute-phase proteins affect red blood cell (RBC) aggregation. Plasma lipids and lipoproteins were also shown to be correlated with RBC aggregation in hypercholesterolemia. However, whether acute-phase proteins promote RBC hyperaggregation in hyper-lipidemic patients is unknown. The main objective of the study was to identify the impact of acute-phase proteins such as fibrinogen (Fib), haptoglobin (Hp), ceruloplasmin (Cp), α1-acid glycoprotein (AGP), α1-antitrypsin (AT), immunoglobulin G (IgG), and albumin (Alb) on RBC aggregation in 35 hyperlipidemic patients. The influence of these proteins in 32 normolipidemic subjects was also determined.

Methods and Results. RBC aggregation parameters reflecting the kinetics of rouleau formation and the adhesive strength between RBCs were measured by laser reflectometry. Multivariate forward stepwise linear regression analyses were performed to study the relationship between RBC aggregation and these acute-phase proteins, total cholesterol (TC), triglycerides (TG), high (HDL-C) and low (LDL-C) density lipo-protein cholesterol, age, gender, body mass index (BMI), mean blood pressure (M_pressure), and smoking habit. The kinetics of rouleau formation was positively correlated with the linear combination of IgG and Hp (r = 0.76, p <0.0001) in hyperlipidemic patients, whereas IgG, smoking, AGP and gender were significant independent predictors in healthy subjects (r = 0.79, p <0.0001). The correlations obtained for the models predicting the adhesive strength between RBCs were 0.69 in patients (Alb, HDL-C, IgG, p <0.002) and 0.71 in healthy individuals (AGP, BMI, p <0.0001).

Conclusion. This study suggests that acute-phase proteins such as IgG, Hp, AGP and Alb influence significantly and in an independent way the level of RBC aggregation. The close association between RBC aggregation and cardiovascular risk factors further strengthens its clinical importance.

Full Text

References

References
1 Vayá A, Martínez M, Carmena R, Aznar J. Red blood cell aggregation and primary hyperlipoproteinemia.. Thrombosis Research 1993; 72: 119-26.
2 Razavian SM, Atger V, Giral PH, Cambillau M, Del-Pino M, Simon AC, Moatti N, Levenson J. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men.. Arteriosclerosis & Thrombosis 1994; 14: 361-6.
3 Caimi G, Presti RL, Canino B, Montana M, Francavilla G, Grifo G, Romano A, Catania A, Sarno A, Vittorio C. Hemorheologic profile of hyperlipidemic patients treated with Gemfibrozil.. Curr Therapeutic Res 1996; 57: 327-35.
4 Martínez M, Vayá A, Martí R, Gil L, Lluch I, Carmena R, Aznar J. Erythrocyte membrane cholesterol/phospholipid changes and hemorheo-logical modification in familial hypercholesterolemia treated with lovastatin.. Thrombosis Research 1996; 83: 375-88.
5 Ruhenstroth-Bauer G, Mössmer G, Ottl J, Koenig-Erich S, Heinemann G. Highly significant negative correlations between erythrocyte aggregation value and serum concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease.. Eur J Clin Invest 1987; 17: 275-9.
6 Neumann FJ, Tillmanns H, Roebruck P, Zimmermann R, Haupt HM, Kübler W. Haemorrheological abnormalities in unstable angina pectoris: A relation independent of risk factor profile and angiographic severity.. Br Heart J 1989; 62: 421-8.
7 Hahn R, Müller-Seydlitz PM, Jöckel KH, Hubert H, Heimburg P. Visco-elasticity and red blood cell aggregation in patients with coronary heart disease.. Angiology 1989; 40: 914-20.
8 Neumann FJ, Katus HA, Hoberg E, Roebruck P, Braun M, Haupt HM, Tillmanns H, Kübler W. Increased plasma viscosity and erythrocyte aggregation: Indicators of an unfavourable clinical outcome in patients with unstable angina pectoris.. Br Heart J 1991; 66: 425-30.
9 Demiroglu H, Barista I, Dündar S. Erythrocyte aggregability in patients with coronary heart disease.. Clinical Hemorheology 1996; 16: 313-7.
10 Tanahashi N, Gotoh F, Tomita M, Shinohara T, Terayama Y, Mihara B, Ohta K, Nara M. Enhanced erythrocyte aggregability in occlusive cerebrovascular disease.. Stroke 1989; 20: 1202-7.
11 Tanahashi N, Fukuuchi Y, Tomita M, Matsuoka S, Takeda H. Erythrocyte aggregability in patients with cerebral infarction with special reference to diabetes mellitus.. Clinical Hemorheology 1993; 13: 253-9.
12 Mchedlishvili G, Shakarishvili R, Aloeva M, Momtselidze N. Elaborated – “Georgian index” of erythrocyte aggregability characterizing the microrheological disorders associated with brain infarct.. Clinical Hemorheology 1995; 15: 783-93.
13 Tanahashi N, Tomita M, Kobari M, Takeda H, Yokoyama M, Takao M, Fukuuchi Y. Platelet activation and erythrocyte aggregation rate in patients with cerebral infarction.. Clinical Hemorheology 1996; 16: 497-505.
14 Tanahashi N, Tomita M, Kobari M, Takeda H, Yokoyama M, Fukuuchi Y. Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction.. J Neurological Sciences 1996; 139: 137-40.
15 Faber CG, Troost J, Vermes I, Lodder J, Kalsbeek-Batenburg EM, Kessels F, Haanen C. Enhanced red blood cell aggregation unrelated to fibrinogen: A possible stroke mechanism in young patients.. Cerebrovasc Dis 1997; 7: 70-6.
16 Hayakawa M, Kuzuya F. Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders.. Angiology 1991; 42: 747-53.
17 Chabanel A, Horellou MH, Conard J, Samama MM. Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post-thrombotic treatment.. Br J Haematology 1994; 88: 174-9.
18 Zuccarelli F, Taccoen A, Razavian M, Chabanel A. Increasing erythrocyte aggregability with the progressive grades of chronic venous insufficiency: importance and mechanisms.. J Cardiovasc Surg 1995; 36: 387-91.
19 Chien S. Blood rheology and its relation to flow resistance and transcapillary exchange, with special reference to shock.. Adv Microcirc 1969; 2: 89-103.
20 Schmid-Schönbein H, Gallasch G, Volger E, Klose HJ. Microrheology and protein chemistry of pathological red cell aggregation (blood sludge) studied in vitro.. Biorheology 1973; 10: 213-27.
21 Schmid-Schönbein H. Critical closing pressure or yield shear stress as the cause of disturbed peripheral circulation?. Acta Chir Scand. 1976: 10-9.
22 Lipowsky HH, Kovalcheck S, Zweifach BW. The distribution of blood rheological parameters in the microvasculature of cat mesentery.. Circ Res 1978; 43: 738-49.
23 Dupuy-Fons C, Brun JF, Pellerin F, Laborde JC, Bardet L, Orsetti A, Janbon C. Relationships between blood rheology and transcutaneous oxygen pressure in peripheral occlusive arterial disease.. Clinical Hemorheology 1995; 15: 191-9.
24 Demiroglu H. The importance of erythrocyte aggregation in blood rheology: Considerations on the pathophysiology of thrombotic disorders.. Blood 1997; 89: 4236.
25 Verstraete M. V, Fuster EJ. Topol. Cardiovascular thrombosis. Thrombo-cardiology and thromboneurology.. Philadelphia, New York, Lippincott:: Raven,; 1998. pp 1-849.
26 Imaizumi K, Shiga T. Effect of immunoglobulins and IgG-fragments on the human erythrocyte aggregation, studied by a rheoscope combined with image analyzer.. Biorheology 1983; 20: 569-77.
27 Rampling MW, Whittingstall P, Linderkamp O. The effects of fibrinogen and its plasmin degradation products on the rheology of erythrocyte suspensions.. Clinical Hemorheology 1984; 4: 533-43.
28 Lowe GDO. Topics in preventive cardiology. The impact of fibrinogen on arterial disease.. The Netherlands:: Excerpta Medica; 1993. pp 3-32.
29 Maeda N, Shiga T. Opposite effect of albumin on the erythrocyte aggregation induced by immunoglobulin G and fibrinogen.. Biochimica & Biophysica Acta 1986; 855: 127-35.
30 Weng X, Cloutier G, Beaulieu R, Roederer GO. Influence of acute-phase proteins on erythrocyte aggregation.. Am J Physiol 1996; 271: H2346-H52.
31 Poggi M, Palareti G, Biagi R, Legnani C, Parenti M, Babini AC, Baraldi L, Coccheri S. Prolonged very low calorie diet in highly obese subjects reduces plasma viscosity and red cell aggregation but not fibrinogen.. Int J Obesity 1994; 18: 490-6.
32 Rothwell M, Rampling MW, Cholerton S, Sever PS. Haemorheological changes in the very short term after abstention from tobacco by cigarette smokers.. Br J Haematology 1991; 79: 500-3.
33 Pignon B, Jolly D, Potron G, Lartigue B, Vilque JP, Nguyen P, Etienne JC, Stoltz JF. Erythrocyte aggregation – Determination of normal values: Influence of age, sex, hormonal state, oestroprogestative treatment, haemato-logical parameters and cigarette smoking.. Nouv Rev Fr Hematol 1994; 36: 431-9.
34 Petralito A. Erythrocyte aggregation in different stages of arterial hypertension.. Thrombosis & Haemostasis 1985; 54: 555.
35 Donner M, Siadat M, Stoltz JF. Erythrocyte aggregation: Approach by light scattering determination.. Biorheology 1988; 25: 367-75.
36 Pignon B, Muller S, Jolly D, Siadat M, Petitfrere E, Vessel B, Donner M, Potron G, Stoltz JF. Validation d‘une méthode d‘approche de l‘agrégation érythrocytaire par retrodiffusion laser. Hémorhéologie et agrégation érythrocytaire.. In Stoltz JF (ed).. Éditions Médicales Internationales. 1988. pp 65-74.
37 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement.. Lancet 1986; 1: 307-10.
38 Chien S. Biophysical behavior of red cells in suspensions.. In: The red blood cell.. Surgenor DM. (ed). New York, San Francisco, London:: Academic Press; 1975. pp 1031-133.
39 Seaman GVF. Electrokinetic behavior of red cells. In: The red blood cell.. Surgenor DM. (ed). San Francisco, London:: Academic Press; 1975. pp 1135to -223.
40 Maeda N, Seike M, Suzuki Y, Shiga T. Effect of pH on the velocity of erythrocyte aggregation.. Biorheology 1988; 25: 25-30.
41 Maeda N. Erythrocyte rheology in microcirculation.. Jpn J Physiol 1996; 46: 1-14.
42 Lowe GDO. Agents lowering blood viscosity, including defibrinogenating agents.. In: Cardiovascular thrombosis: Thrombocardiology and thromboneurology.. Verstraete M, Fuster V, Topol EJ. (eds). Philadelphia, New York, Lippincott:: Raven; 1998. pp 321-33.
43 Chesebro JH, Fuster V. Valvular heart disease and prosthetic heart valves.. In: Cardiovascular thrombosis: Thrombocardiology and thrombon urology.. Verstraete M, Fuster V, Topol EJ. (eds). Philadelphia, New York, Lippincott:: Raven; 1998. pp 365-94.
44 Harker LA, Mann KG. Thrombosis and fibrinolysis.,. In: Cardiovascular thrombosis: Thrombocardiology and thromboneurology.. Verstraete M, Fuster V, Topol EJ. (eds). Philadelphia, New York, Lippincott:: Raven; 1998. pp 3-22.
45 Maeda N, Seike M, Kume S, Takaku T, Shiga T. Fibrinogen-induced erythrocyte aggregation: erythrocyte-binding site in the fibrinogen molecule.. Biochimica & Biophysica Acta 1987; 904: 81-91.
46 Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh artery study.. Circulation 1993; 87: 1915-20.
47 Ernst E. Fibrinogen: An important risk factor for atherothrombotic diseases.. Annals of Medicine 1994; 26: 15-22.
48 Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients.. Arterioscler Thromb Vasc Biol 1996; 16: 351-6.
49 Rampling MW, Martin G. Albumin and rouleaux formation.. Clinical Hemorheology 1992; 12: 761-5.
50 Putnam FW. The plasma proteins: Structure, function, and genetic control.. Orlando. San Diego, New York, London, Toronto, Montreal, Sydney, Tokyo:: Academic Press, Inc.; 1984. pp 1-400.
51 Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis.. Am Heart J 1988; 113: 589-97.
52 Simon E, Razavian SM, Le Beyec J, Atger V, Paul JL, Simon A, Moatti N, Levenson J. Influence of lipoprotein subfractions on dextran- and fibrinogen-induced erythrocyte aggregation.. Clinical Hemorheology 1995; 15: 667-76.